What does PHARMABAK do?

PHARMABAK is a pharmacy in Sint-Jans-Molenbeek. Private Limited, started on 26 January 2015, 1 establishment.

What is the address of PHARMABAK?

The registered office of PHARMABAK is located at Ferdinand Elbersstraat 5, 1080 Sint-Jans-Molenbeek.

Is PHARMABAK still active?

Yes. According to the CBE (2 November 2026) PHARMABAK is active, legal situation “Normale toestand”, started on 26 January 2015.

Is PHARMABAK registered on Peppol?

Yes, PHARMABAK is registered on the Peppol network with ID 0208:0578906094.

What is the enterprise number of PHARMABAK?

The enterprise number of PHARMABAK is BE0578906094.

When was PHARMABAK founded?

PHARMABAK was founded on 26 January 2015.

Who are the directors of PHARMABAK?

According to the 2025 annual accounts, the directors of PHARMABAK are: Metin Bakar, DANIEL BAKAR.

Is PHARMABAK a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 January 2015; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMABAK make in 2025?

PHARMABAK recorded a loss after taxes of € 29,717 in financial year 2025.

What is the revenue of PHARMABAK?

As a small company, PHARMABAK is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -10,053.

PHARMABAK (Private Limited) - Sint-Jans-Molenbeek

Dossier PHARMABAK, printed on 2 November 2026 from databakkes.be/en/0578906094/pharmabak. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMABAK from Sint-Jans-Molenbeek, company number BE0578906094, closed financial year 2025 with a result of € -29,717 after tax. For that financial year PHARMABAK recorded a gross margin of € -10,053 and equity of € 51,008. Compared with financial year 2024, the result moved from € 4,082 to € -29,717. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.

What it is worth Healthy

€ 51,008

▼ 37% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -29,717

▼ still € 4,082 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 24,837

▲ 84% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 32,408.

People and assets in 2025

Wage cost

€ 2,214

▲ € 2,080 vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 93,166

▼ 32% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 9,190 Gross margin 2022: € 9,190 First fiscal year in the series	€ -3,400 Gross margin 2023: € -3,400 ▼ € 12,590 vs 2022 (€ 9,190) Unfavourable step	€ 16,087 Gross margin 2024: € 16,087 ▲ € 19,487 vs 2023 (€ -3,400) Favourable step	€ -10,053 Gross margin 2025: € -10,053 ▼ € 26,140 vs 2024 (€ 16,087) Unfavourable step	▼ € 26,140
Profit after taxes	€ 3,823 Profit after taxes 2022: € 3,823 First fiscal year in the series	€ -6,252 Profit after taxes 2023: € -6,252 ▼ € 10,076 vs 2022 (€ 3,823) Unfavourable step	€ 4,082 Profit after taxes 2024: € 4,082 ▲ € 10,334 vs 2023 (€ -6,252) Favourable step	€ -29,717 Profit after taxes 2025: € -29,717 ▼ € 33,799 vs 2024 (€ 4,082) Unfavourable step	▼ € 33,799
Equity	€ 82,896 Equity 2022: € 82,896 First fiscal year in the series	€ 76,644 Equity 2023: € 76,644 ▼ 8% vs 2022 (€ 82,896) Unfavourable step	€ 80,725 Equity 2024: € 80,725 ▲ 5% vs 2023 (€ 76,644) Favourable step	€ 51,008 Equity 2025: € 51,008 ▼ 37% vs 2024 (€ 80,725) Unfavourable step	▼ 37%
Total debts	€ 141,893 Total debts 2022: € 141,893 First fiscal year in the series	€ 262,543 Total debts 2023: € 262,543 ▲ 85% vs 2022 (€ 141,893) Unfavourable step	€ 342,505 Total debts 2024: € 342,505 ▲ 30% vs 2023 (€ 262,543) Unfavourable step	€ 306,507 Total debts 2025: € 306,507 ▼ 11% vs 2024 (€ 342,505) Favourable step	▼ 11%
Cash	€ 30,118 Cash 2022: € 30,118 First fiscal year in the series	€ 13,439 Cash 2023: € 13,439 ▼ 55% vs 2022 (€ 30,118) Unfavourable step	€ 13,487 Cash 2024: € 13,487 Unchanged (€ 13,439) Favourable step	€ 24,837 Cash 2025: € 24,837 ▲ 84% vs 2024 (€ 13,487) Favourable step	▲ 84%
Retained profit	€ 64,296 Retained profit 2022: € 64,296 First fiscal year in the series	€ 58,044 Retained profit 2023: € 58,044 ▼ 10% vs 2022 (€ 64,296) Unfavourable step	€ 62,125 Retained profit 2024: € 62,125 ▲ 7% vs 2023 (€ 58,044) Favourable step	€ 32,408 Retained profit 2025: € 32,408 ▼ 48% vs 2024 (€ 62,125) Unfavourable step	▼ 48%
Balance sheet total	€ 224,789 Balance sheet total 2022: € 224,789 First fiscal year in the series	€ 339,187 Balance sheet total 2023: € 339,187 ▲ 51% vs 2022 (€ 224,789) Unchanged	€ 423,230 Balance sheet total 2024: € 423,230 ▲ 25% vs 2023 (€ 339,187) Unchanged	€ 357,515 Balance sheet total 2025: € 357,515 ▼ 16% vs 2024 (€ 423,230) Unchanged	▼ 16%

Key figures of PHARMABAK, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMABAK?

What happened at PHARMABAK in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 23, 2026 New annual accounts for financial year 2025: loss of € 29,717 (▼ € 33,799 vs 2024). Source: NBB ↗
Jan 26, 2015 New establishment in Sint-Jans-Molenbeek. KBO
Jan 26, 2015 Start of the company according to the CBE. KBO

In short

From € 3,823 profit in 2022 to € 29,717 loss in 2025.

Paid € 1,398 in corporate taxes since 2022.

Best year ever: 2024, with € 4,082 profit.

Original PDFs at the National Bank ↗

Management

Metin Bakar DANIEL BAKAR

WEST PHARMA

B&B PHARMA

PHARMABAK

Di-NY

Behind PHARMABAK are Metin Bakar and DANIEL BAKAR. Metin Bakar is also behind WEST PHARMA, B&B PHARMA, "WESTLAND PHARMA", Pharma City 2 and BKR. DANIEL BAKAR is also behind Di-NY.

Directors

According to the 2025 annual accounts

Metin Bakar

Director

Also active at: WEST PHARMA, B&B PHARMA, "WESTLAND PHARMA", Pharma City 2, BKR

DANIEL BAKAR

Director

Also active at: Di-NY

Establishments

Establishment units

Physical locations of this company

Registered office

Ferdinand Elbersstraat 5

1080 Sint-Jans-Molenbeek

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0578.906.094
VAT number: BE 0578.906.094
Registered office: Ferdinand Elbersstraat 5, 1080 Sint-Jans-Molenbeek
Names & denominations: PHARMABAK
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 26 January 2015
Peppol: Active · Active since 26 Nov 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗